Metastatic colorectal carcinoma patients: The Glasgow Prognostic Score (GPS) at the era of anti-EGFR therapies

被引：0
|
作者：
Dreanic, J. [1 ]
Maillet, M. [1 ]
Dhooge, M. [1 ]
Cessot, A. [2 ]
Mir, O. [2 ]
Brezault, C. [1 ]
Goldwasser, F. [2 ]
Chaussade, S. [1 ]
Coriat, R. [1 ]
机构：
[1] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Gastroenterol, Paris, France
[2] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Oncol, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2290
引用
收藏
页码：S525 / S525
页数：1
相关论文
共 50 条
  • [21] Rational drug combinations to improve anti-EGFR targeted therapies in metastatic colorectal cancer
    Bertotti, Andrea
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
    Zhou, Jing
    Ji, Qing
    Li, Qi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [23] Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
    Jing Zhou
    Qing Ji
    Qi Li
    Journal of Experimental & Clinical Cancer Research, 40
  • [24] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11) : 737 - 747
  • [25] ANTI-EGFR ANTIBODY RECHALLENGE IN CHEMOREFRACTORY PATIENTS WITH METASTATIC COLORECTAL CANCER
    Kajitani, Tatsuhiro
    Makiyama, Akitaka
    Arita, Shuji
    Kumagai, Hozumi
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Esaki, Taito
    ANNALS OF ONCOLOGY, 2014, 25
  • [26] A method to assess KRAS/BRAF genotype in patients with metastatic colorectal cancer (mCRC) elligible for anti-EGFR therapies
    Lamy, A.
    Labourier, E.
    Prigneau, O.
    Di Fiore, F.
    Sesbouea, R.
    Sabourin, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [27] A Prognostic Indicator of Survival in Metastatic Colorectal Cancer Patients in the Era of Molecular-Targeted Agents: The Modified Glasgow Prognostic Score
    Dreanic, Johann
    Dhooge, Marion
    Brezault, Catherine
    Mir, Olivier
    Chaussade, Stanislas
    Coriat, Romain
    ONCOLOGY, 2014, 86 (01) : 44 - 45
  • [28] Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
    F Di Fiore
    F Charbonnier
    B Lefebure
    M Laurent
    F Le Pessot
    P Michel
    T Frebourg
    British Journal of Cancer, 2008, 99 : 551 - 552
  • [29] Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
    Di Fiore, F.
    Charbonnier, F.
    Lefebure, B.
    Laurent, M.
    Le Pessot, F.
    Michel, P.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2008, 99 (03) : 551 - 552
  • [30] Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis
    Elie Kassouf
    Samer Tabchi
    Mustapha Tehfe
    BioDrugs, 2016, 30 : 95 - 104
12345